No matches
Pulmonology

ERS 2025 | The Knowns and Unknowns in the COPD Landscape

Join Profs. Dave Singh and Klaus Rabe as they examine the clinical relevance of exacerbations, lung function, symptoms, quality of life, and comorbidities in COPD, as well as the evolving concept of disease stability and what that could mean for treatment planning and the future of COPD care.
Dave Singh
Klaus Rabe
FBPhS, MD, FERS
Dave Singh +1 more

Related resources

The Compounded Burden of CRSwNP and Asthma

The Compounded Burden of CRSwNP and Asthma

interactivity
Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Infographic
ERS 2025 | Less Flare, More Function: Recognizing the Full Spectrum of COPD Patient Outcomes

ERS 2025 | Less Flare, More Function: Recognizing the Full Spectrum of COPD Patient Outcomes

expert video
Understanding the Clinical Impact of Mucus Plugs in COPD

Understanding the Clinical Impact of Mucus Plugs in COPD

Infographic
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Phenotypes and Endotypes of COPD

Phenotypes and Endotypes of COPD

expert video
2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs

2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs

expert video
2025 ADVENT Forum | Potential for Disease Modification in the Airway

2025 ADVENT Forum | Potential for Disease Modification in the Airway

expert video
2025 ADVENT Forum | Latest Clinical Data from the COPD Biologic Treatment Landscape

2025 ADVENT Forum | Latest Clinical Data from the COPD Biologic Treatment Landscape

expert video
Lung Function Decline: Why it Matters and What’s at Stake for Patients

Lung Function Decline: Why it Matters and What’s at Stake for Patients

interactivity
Eosinophils: A Biomarker in COPD

Eosinophils: A Biomarker in COPD

Infographic
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

interactivity
Understanding IL-33: A Key Factor in COPD Pathogenesis

Understanding IL-33: A Key Factor in COPD Pathogenesis

interactivity
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

expert video
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

videoanimation
Worsening Disease Results in a Vicious Cycle of COPD

Worsening Disease Results in a Vicious Cycle of COPD

interactivity
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity
Uncovering the Impact of Moderate COPD Exacerbations

Uncovering the Impact of Moderate COPD Exacerbations

interactivity

Learning objectives

  • Recognize the clinical impact of exacerbations, lung function, symptoms, quality of life, and comorbidities in COPD
  • Discuss the evolving concept of disease stability and its potential role in treatment planning
  • Explore limitations in current evidence and the future direction of COPD care
Tags
exacerbationslung functionsymptomssymposiumquality of lifecomorbidities
MAT-GLB-2601664 - 1.0 - 04/2026

About these experts

Pulmonology
FBPhS, MD, FERS

Dave Singh

Respiratory Physician, Professor of Clinical Pharmacology and Respiratory Medicine |University of Manchester, Manchester, United Kingdom

Pulmonology
MD, PhD, FERS

Klaus Rabe

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LatviaChange country/region